Cytochrome P450 immobilisation as a route to bioremediation/biocatalysis  by Lamb, Stephen B. et al.
Cytochrome P450 immobilisation as a route to
bioremediation/biocatalysis
Stephen B. Lamba, David C. Lambb, Steven L. Kellyb, David C. Stuckeya;*
aDepartment of Chemical Engineering, Imperial College, Prince Consort Road, London, SW7 2BY, UK
bInstitute of Biological Sciences, University of Wales Aberystwyth, Aberystwyth SY23 3DA, UK
Received 11 June 1998
Abstract The diverse substrate specificity of the cytochrome
P450 (P450; CYP) enzyme superfamily offers the opportunity to
develop enzymatic systems for environmental detoxification and
biotransformations of drugs, pesticides and fine chemicals. Here
we report on the immobilisation of a fusion protein between plant
cytochrome P450-71B1 (CYP71B1) and its electron donor, plant
NADPH cytochrome P450 reductase using an oil-in-water
macro-emulsion, termed polyaphron, which contains a proportion
of internal organic phase (P) greater than 0.74. Efficiency of
P450 immobilisation was greater than 85%, and in this state
enzymatic activity could be measured for more than 24 h at 15‡C.
Chlortoluron, a recalcitrant herbicide pollutant in the environ-
ment, was shown to be metabolised, with the major metabolite
(N-monodemethylated chlortoluron) being separated from the
substrate due to partitioning into the aqueous phase. The
turnovers exhibited superactivity compared with those obtained
using free enzyme located in membranes prepared following
heterologous expression in Saccharomyces cerevisiae and Es-
cherichia coli. The potential to exploit the unprecedented
catalytic diversity of the P450 superfamily in biocatalysis is
discussed.
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1. Introduction
The cytochrome P450 superfamily is widely distributed in
various forms of life and participates in a range of oxygen-
ation reactions of diverse substrates including pharmaceuti-
cals, carcinogens, pesticides and pollutants [1,2]. Its unique
catalytic chemistry and substrate speci¢city are well known
and exploited in whole-cell biotransformations, such as the
hydroxylation of corticosteroids by fungi [3]. However, using
biological engineering techniques to exploit P450 systems for
the synthesis of highly speci¢c chemicals and detoxifying en-
vironmental pollutants remains a challenge in biotechnology.
Enzyme immobilisation is a technique that facilitates bio-
catalyst separation from the product, localisation within a
reactor, improved enzymatic stability/activity retention, con-
tinuous operation over extended periods of time, and the pos-
sibility of obtaining enzyme superactivity [4,5]. The use of
polyaphrons as an immobilisation technique has been previ-
ously described for other enzymes with various degrees of
success. The immobilisation of lipase from Candida cylindra-
cea was successful with over 80% [6] of the enzyme being
e¡ectively retained on the support and activity comparable
to the free enzyme being achieved. However, for K-chymo-
trypsin, a large proportion of the enzyme could be immobi-
lised, but with virtually no resulting activity [7].
Polyaphrons are similar to oil-in-water High Internal Phase
Ratio (often termed ‘concentrated’) emulsions, containing a
greater proportion of internal organic phase than is associated
with hexagonal close packing of spheres (ratio of internal/con-
tinuous, P= 0.74) [8]. In this type of polyaphron formulation,
they exist as polyhedral cells separated by thin, planar ¢lms of
continuous aqueous phase [9,10]. They are formed by mixing a
relatively non-polar organic solvent containing surfactant into
an aqueous surfactant solution, with stable formulations last-
ing for many months without visible deterioration. The poly-
aphron phase can be homogeneously dispersed into a bulk
aqueous phase with only minimal agitation, and under these
conditions form discrete micron sized droplets of organic sol-
vent (typical Sauter mean diameter 18 Wm), which can then be
referred to as Colloidal Liquid Aphrons (CLAs). The general
applicability of this technique in the immobilisation of com-
mercially important biocatalytic enzymes remains unresolved.
In this work, the immobilisation of plant cytochrome P450-
71B1 fused to its electron donor, NADPH cytochrome P450
reductase, in an active form, is described. The great diversity
of organic structures that can serve as substrates of P450s
makes their application in enzyme-based biotechnological
processes attractive, including the rapid prediction of the met-
abolic fate of drugs and pesticides metabolised by human and
plant P450s. In addition, P450s combine the advantages asso-
ciated with biocatalysts for organic syntheses, i.e. chemoselec-
tivity including stereoselectivity and regioselectivity. The in-
vestigation of P450 immobilisation is a logical route towards
more e⁄cient biocatalysis/bioremediation technologies, and
here we report on the successful immobilisation of a puri¢ed
eukaryotic P450 monooxygenase fused to its electron donor.
2. Materials and methods
2.1. Genetic engineering
Plasmid pSP19g10L, which is derived from pSPORT, was used for
P450 expression. This plasmid contains the inducible tac promoter
[11]. Expression constructs containing a fusion protein comprising
both plant CYP71B1 and NADPH-cytochrome P450 reductase have
been described previously [12]. For successful bacterial expression,
modi¢cations to the N-terminal region of CYP71B1 were carried
out to encode the codons representing the initial eight amino acids
of CYP17A [13]. All manipulations were checked by diagnostic re-
striction analysis, and the successful constructs, CYP71B1:CPR, were
sequenced to con¢rm the integrity of the clone.
2.2. Enzyme preparation
E. coli suspensions from a 500-ml culture were resuspended in 25 ml
10 mM potassium phosphate bu¡er, pH 7.4, containing 1 mM EDTA
and 20% (v/v) glycerol. Lysozyme (0.5 mg/ml) was added and the
suspension left on ice for 30 min. Phenyl methyl sulphonyl £uoride
(PMSF) was added to a ¢nal concentration of 1 mM and the mixture
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was sonicated on ice with a Soniprep cell disruptor using six 20-s
pulses with 20-s intervals at 80% of the maximum power. Cell debris
was removed by centrifugation at 5000Ug for 10 min and the mem-
branes pelleted by centrifugation at 100 000Ug for 60 min. E. coli
membranes were diluted to a concentration of 3.0 mg/ml in 10 mM
potassium phosphate bu¡er (pH 7.5) containing 20% (v/v) glycerol,
0.5 mM EDTA, 0.1 mM dithiothreitol, and 1.0% Emulgen 911 (w/v).
All procedures were carried out at 4‡C. The solubilised membrane was
stirred for 30 min and subjected to centrifugation at 100 000Ug for 60
min. The clari¢ed supernatant was then dialysed with 10 mM potas-
sium phosphate bu¡er (pH 6.5) containing 20% glycerol (v/v) and
applied to a hydroxyapatite column that had been equilibrated with
the dialysis bu¡er. For removal of detergent and PMSF, the column
was washed extensively with the equilibration bu¡er, and the deter-
gent monitored at 280 nm. P450 (red colour) was eluted from the
column with 500 mM potassium phosphate bu¡er (pH 7.5) containing
20% (v/v) glycerol and 0.1 mM DTT. The P450 fractions were dia-
lysed against 10 mM potassium phosphate bu¡er (pH 7.5) containing
1 mM EDTA, 0.1 mM DTT and 20% (v/v) glycerol to lower the
phosphate concentration. The protein was stored at 380‡C until fur-
ther use.
2.3. Polyaphron preparation
Polyaphron phases were prepared by the dropwise addition of the
organic phase containing non-ionic surfactant (1% (w/v) Softanol 30)
into a foaming aqueous solution containing another non-ionic surfac-
tant (1% (w/v) Synperonic A20 in RO water), and the desired con-
centration of the enzyme. The initial volume of the aqueous phase was
typically 2 ml, which was stirred at approximately 800 rpm, and the
organic phase was added at an average £ow rate of 0.5 ml/min until
the desired phase volume ratio of 4 was reached (PVR = Vorg/Vaq).
The polyaphrons formed containing the enzyme were used on the
day of manufacture.
2.4. Determination of protein loss
Loss of CYP71B1:fusion from the CLAs after dispersion was de-
termined at 417 nm using a Shimadzu UV2101 double beam spectro-
photometer with an accuracy of þ 8%. The polyaphron phase was
dispersed into a 50 mM bu¡er solution of known pH at a volume
ratio of 1:1 by gentle shaking. After 1 h, most of the aphrons had
risen forming a separate phase, the bottom aqueous phase was then
¢ltered through a syringe ¢lter (Sartorius, 0.2 Wm) to obtain a CLA-
free sample of the continuous phase. The enzyme concentration in the
aqueous phase was estimated according to Omura and Sato [14], and
the percentage loss of the enzyme determined by mass balance.
2.5. Determination of cytochrome P450 activity
Polyaphrons were formulated containing enzyme, and dispersed
into bu¡er (pH 7) containing NADPH (¢nal concentration 1 mM),
and ¢nally [14C]chlortoluron was added. The reaction was incubated
at 37‡C for 3 h, with the reaction vessels being continually stirred
throughout the experiment. The CLAs were then allowed to separate
from the aqueous phase and the products tested and identi¢ed by
autoradiography by reference to known products. For quanti¢cation
by TLC, the metabolite bands were excised and radioactivity assessed
by liquid scintillation counting. The reaction for erythromycin was
also similar; 5 ml of erythromycin (1 mM solution) was mixed with
an equal volume of NADPH (1 mM ¢nal concentration). The poly-
aphron phase (5 ml) was then added, giving a volume ratio of 1:1,
and incubated at 37‡C for 30 min. A sample was then taken, ¢ltered
and tested for formaldehyde using the NASH reagent. Control experi-
ments involved incubation with CLAs without the enzyme and CLAs
immobilised with enzyme prepared from E. coli membranes expressing
the null vector.
3. Results
3.1. Genetic manipulation and protein expression
CYP71B1:CPR was constructed and expressed in E. coli as
a modi¢ed protein where the native N-terminal sequence was
replaced with that employed for the heterologous expression
of CYP17A in E. coli [13], thus incorporating codons that
facilitate expression in E. coli. CYP71B1:CPR levels were
low (29 nmol/l), however, supplementing the growth medium
with the haem precursor N-aminoeluvinic acid increased the
expression levels approximately twofold. The CPR activity of
the fusion protein was calculated to be 650 nmol cytochrome c
reduced/min per mg membrane protein re£ecting an equiva-
lence of CYP and CPR levels [12].
3.2. Formulation of CLAs containing CYP71B1:CPR
To study the activity and applications of CLA-immobilised
CYP71B1:CPR, it was ¢rst necessary to formulate stable
polyaphrons containing the fusion protein. With an initial
concentration of the P450 of 0.4 mg/ml in the aqueous phase,
the CYP71B1:CPR loading of the aphrons obtained was
0.068 mg protein/ml polyaphron at pH 7. The immobilisation
of the fusion protein did not seem to be a¡ected by the pH of
the bulk aqueous phase into which it was dispersed (Fig. 1).
The spectral properties of the free CYP71B1:CPR fusion
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Fig. 1. E¡ect of continuous phase pH on the immobilisation of the
cytochrome P450/NADPH cytochrome P450 reductase fusion pro-
tein (CYP71B1:CPR). Aphrons formulated from 1% (w/v) Softanol
30 in decane and 1% (w/v) SDS in water to PVR 4. Results are the
average of three determinations.
Fig. 2. Spectrophotometric absorption spectra of free, puri¢ed CY-
P71B1:reductase fusion. Solid line: oxidised form; dashed line: re-
duced carbon monoxide di¡erence complex; and dashed/dotted line:
aqueous phase after immobilisation on CLAs.
Table 1
Rates of plant CYP71B1:reductase fusion-catalysed erythromycin
N-demethylation and chlortoluron metabolism
Compound Activity (nmol product(s) formed/min/nmol
CYP71B1)
Control Free Immobilized
Erythromycin ^ 1.2 þ 0.8 11.0 þ 1.2
Chlortoluron ^ 0.9 þ 0.7 10.2 þ 1.5
S.B. Lamb et al./FEBS Letters 431 (1998) 343^346344
showed the oxidised form exhibiting a spectral maximum at
417 nm corresponding to the protein haem, and the carbon
monoxide reduced absorbance maximum located at 448 nm
(Fig. 2). For the immobilised form, spectra were produced
after immobilisation and subsequent dispersion for the re-
maining aqueous phase after £otation. The lack of a spectral
maximum at either 417 or 448 nm indicated that the immobi-
lisation of the CYP71B1:CPR fusion had been successful.
3.3. CYP71B1:CPR immobilised activity
To investigate the activity of CLA-immobilised
CYP71B1:CPR, the N-demethylation of the model P450 sub-
strate, erythromycin (Fig. 3), was measured. In addition, the
ability of immobilised CYP71B1:CPR to metabolise
[14C]chlortoluron (Fig. 3), a recalcitrant pollutant, was as-
sessed and the major metabolite was shown to be N-mono-
demethylated chlortoluron. Immobilised CYP71B1:CPR
could demethylate erythromycin with a turnover of 11 nmol
product formed/min/nmol P450. This was an approximately
10-fold higher activity when compared with free enzyme pre-
pared from heterologously expressing yeast and E. coli. Fur-
thermore, chlortoluron was metabolised by the immobilised
system with a turnover of 10.2 nmol N-monodemethylated
chlortoluron formed/min/nmol P450 compared with 2.1
nmol N-monodemethylated chlortoluron formed/min nmol
P450 for the free enzyme (Table 1). These results show the
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Fig. 4. Immobilised plant CYP71B1:reductase fusion catalytic cycle for chlortoluron N-monodemethylation. Chlortoluron partitions to the
CLA oil phase where it has access and binds to the hydrophobic active site of the oxidised P450. Electrons are transferred via the fused plant
NADPH cytochrome P450 reductase from NADPH. In the ¢nal step the complex decomposes to give the N-monodemethylated product, which
partitions into the aqueous phase of the system, regenerating the oxidised P450 form.
Fig. 3. Chemical formulae of erythromycin and chlortoluron.
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CYP71B1:CPR becomes ‘superactive’ on immobilisation, a
phenomenon shown to occur for the immobilisation of other
enzymes [3,4].
4. Discussion
There has been a great deal of interest in the exploitation of
the P450 enzymes for practical applications. To date the use
of P450 enzymes in industrial processes has been restricted to
in vivo biotechnology whereby an organism expressing a P450
form(s) has been manipulated to achieve commercial success.
Examples include the manipulation of £ower colour [15], the
synthesis of progesterone and pregnenolone in yeast [16], and
the use of P450sca in Streptomyces carbophilus in the produc-
tion of the anti-cholesterol agent pravastatin [17]. Further-
more, the use of P450 enzymes in bioremediation is now be-
coming of increasing interest with experiments revealing that
P450 from Pleurotus is needed for bioremediation and lignin
degradation [18,19]. Thus it can be expected that rapid prog-
ress will be made in the biotechnological uses of P450 enzymes
in the coming years.
Nevertheless, despite the applied potential of P450 enzymes,
problems still exist in P450 biochemistry which need to be
solved before they can be used industrially. Firstly, prior to
monooxygenation, cytochrome P450 derives the electrons in-
volved in the molecular splitting of atmospheric oxygen from
another protein, namely NADPH-cytochrome P450 reductase.
Consequently, immobilisation of P450 alone would not result
in catalytic activity. In this study, we demonstrate the e⁄cient
immobilisation of plant P450 fused to its electron donor thus
representing immobilisation of the complete eukaryotic P450
monooxygenase system. Previous studies using crude rat mi-
crosomal liver fractions were only immobilised with low e⁄-
ciency and reduced activity using Romicon PM 10 polysul-
phone anisotropic hollow ¢bres [20]. It has been proposed
that immobilisation on CLAs may be due to electrostatic or
hydrophobic interactions [6]. The immobilisation of the fusion
protein did not seem to be dependent on pH or the presence
of non-ionic surfactants, and this tends to indicate that im-
mobilisation may be predominantly due to hydrophobic inter-
actions. The overall molecular weight of the fusion protein is
125 000 Da (MW of P450 V53 000 Da and MW of reductase
V72 000 Da). This large molecular weight would indicate that
the enzyme has a considerable hydrophobic core, which would
be attracted to the hydrophobic surface of the CLAs. The
P450 is a membrane bound enzyme and it is likely to be
relatively non-polar. Hence, it would tend to associate itself
more readily with the oil-water interface (Fig. 4).
In our study the enzyme system was active in its ability
to N-demethylate erythromycin and chlortoluron. Further-
more, comparison of the immobilised enzyme with the free
enzyme in chlortoluron metabolism revealed the immobilised
enzyme to have greater activity. Similarly, immobilised
CYP71B1:CPR had greater activity towards N-demethylation
of erythromycin when compared to the free form. This may be
due to structural activation of the CYP71B1:CPR complex
brought about by its localisation at an oil/water interface
with the CLAs, greater access or a⁄nity of the substrate mol-
ecules to the active site of the P450, or more e⁄cient electron
transport. Many enzymes, including P450, are associated with
non-polar cellular components such as membranes [21], and in
these cases the natural microenvironment will be less polar
than bulk water and so this may lead to activation of the
enzyme.
The present study demonstrates the feasibility of direct im-
mobilisation of a cytochrome P450/NADPH cytochrome P450
reductase fusion protein for carrying out highly speci¢c hy-
droxylation of a recalcitrant pollutant. Other studies for har-
nessing P450 enzymes for practical applications have involved
driving the P450 by supplying electrons to the redox partners
by the use of a platinum electrode [22,23]. However, current
limitations to these systems include problems in separating the
product from the bioreactor components, and direct reduction
of the reductase partner proteins from eukaryotic systems
which would require other electrode and/or bioreactor design
strategies [23]. The development of expression systems allow-
ing high level production of enzyme coupled with develop-
ments in the mechanical stability of immobilised supports
may serve as an alternative route towards improving industri-
al processes. For the P450 studied here applications could
include bioremediation strategies and predicting the metabolic
fate of pesticides in the agrochemical industry. Other drug-
metabolising P450 enzymes of humans may be used to pro-
duce metabolites of drugs/xenobiotics for toxicological evalu-
ation as well as for biotransformations generally.
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